Zenosense Inc. ZENO Archives - Page 4 of 4

WednesdayMay 21, 2014 9:24 am

Zenosense, Inc. (ZENO) Provides Update on Staph Infection Detection Device’s Development

Today before the opening bell, Zenosense shared an update regarding its device for the detection of the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug”, which is also known as staph infection. Since the company signed the development agreement with its partner and a leading European sensor detector, the Sgenia Group, six months ago, notable progress has been made. Since the device’s development commenced in December 2013, a number of things have been completed: • A technical review of volatile organic compounds produced by MSSA (Methicillin-susceptible S.aureus) and MRSA in vitro or exhaled breath has been undertaken. Several compounds, including compounds that could…

FridayMay 16, 2014 6:05 pm

Zenosense, Inc. (ZENO) Opening Up New Solutions for Early HAI and Cancer Detection

Under an agreement with a leading European sensor developer, Zenosense is developing a device intended for the detection of the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug", commonly known as the staph infection. Zenosense has exclusive global licensing rights for the sensory device, which is being designed for use in hospitals and other healthcare settings. Under its development and exclusive global licensing agreement, Zenosense also has rights to development and marketing of sensory devices that can detect certain types of cancer within their early stages. The company notes that there is a strong need for an early-stage cancer detection device. It believes…

ThursdayMay 08, 2014 11:32 am

Zenosense, Inc. (ZENO) Extends Agreement with Sgenia Group to Include Sensory Devices

Zenosense is a healthcare technology company focused on developing and marketing a device for use in hospitals and various healthcare environments to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," has announced that the company has extended its agreement with the Sgenia Group ("Sgenia") to include cancer sensory devices. Under the terms of the extension, Zenosense has the optional right to fund the development of prospective cancer sensory devices that may be based on the Sgenia technology. Subject to providing funding, the company will have the right to make, market, and sell the resulting devices should they be developed. ZENO believes…

FridayMay 02, 2014 2:54 pm

Zenosense, Inc. (ZENO) Bacterial Contamination Detector Could Save U.S. Healthcare Industry Billions

Leveraging an agreement with a leading European sensor developer, Zenosense is developing a novel device that detects Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, commonly referred to as “staph.” The company intends to market the developed product primarily to hospitals to combat healthcare-associated infections (HAIs). The Centers for Disease Control and Prevention (CDC) estimate that one in every 20 patients treated in U.S. hospitals develop an HAI, which are directly responsible for at least 23,000 deaths per year in the United States alone. Industry figures estimate the annual costs of treating hospitalized MRSA patients specifically to be between $3.2 billion and…

ThursdayApr 24, 2014 1:28 pm

Zenosense, Inc. (ZENO) is “One to Watch”

Zenosense is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient. Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention…

MondayApr 21, 2014 10:46 am

Zenosense, Inc. (ZENO) Leading the Way for Blockbuster Medical Diagnostic Measures of Healthcare-Associated Infections

An emerging healthcare technology company, Zenosense is the holder of an exclusive global license agreement for the development and marketing of a device for use in hospitals to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA). MRSA is a super bug with tremendous implications for strong adverse effects in healthcare delivery: according to the Centers for Disease Control and Prevention (CDC), MRSA is responsible for over 11,000 deaths and 80,000 invasive infections per year in just the United States. Annually, those infections give rise to around $3.2-4.2 billion in U.S. treatment costs. Overall, the CDC reports that these statistics do not…

ThursdayApr 10, 2014 10:24 am

Zenosense, Inc. (ZENO) Enters $475,000 Securities Purchase Agreement

Today, Zenosense, an emerging healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings for detection of the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug”, announced that it had entered into a securities purchase agreement with an accredited investor. According to the agreement’s terms, Zenosense will engage in an initial sale of 55,556 shares of common stock at a gross sale price of $25,000. The accredited investor has agreed to the purchase of an additional 900,000 shares of common stock in four additional purchases, subject to certain conditions. The additional purchases will be commenced…

ThursdayApr 03, 2014 9:21 am

Zenosense, Inc. (ZENO) Commences New Company Website

Today, Zenosense announced the launch of a new company website. Based in Valencia, Spain, Zenosense is a healthcare technology company engaging in the development and marketing of a detection device for use in hospitals and other healthcare settings. Zenosense’s device is being engineered to focus on detection of the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug". The new company website includes comprehensive details about Zenosense’s MRSA-detection device and its initiatives in its development, challenges for healthcare providers created by MRSA, and the device’s development team. SEC regulatory filings, news releases, stock performance, and other company-related information can be accessed there as well.…

Site Search

Company Search

Tag: Zenosense Inc. ZENO